-- 根据FactSet调查的分析师报告，KalVista Pharmaceuticals (KALV) 的平均评级为“增持”，平均目标价为31.60美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Related Articles
International
April S&P Global US Final Manufacturing PMI 54.5 Vs. Unrevised Expected 54.0 Flash, March 52.3
Australia
UBS Adjusts Price Target on LPL Financial to $395 From $380, Maintains Buy Rating
LPL Financial (LPLA) has an average rating of overweight and mean price target of $403, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $320.57, Change: $-13.56, Percent Change: -4.06%
$LPLA
Australia
Morgan Stanley Adjusts Trane Technologies PT to $565 From $535, Maintains Overweight Rating
Trane Technologies (TT) has an average rating of overweight and mean price target of $512.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $494.72, Change: $+2.41, Percent Change: +0.49%
$TT